Duration of serological response to canine parvovirus-type 2, canine distemper virus, canine adenovirus type 1 and canine parainfluenza virus in client-owned dogs in Australia

[Prevention of canine parvovirosis - Part 1: Humoral and cellular immunity]

Canine parvovirosis remains a common and highly infectious disease. Thus, adequate protection is essential for all dogs at any time. In this, humoral immunity plays an essential role. The presence of antibodies in adult dogs suggests immunity against the disease, and nearly all adult dogs possess antibodies (either due to previous vaccination or infection). Meanwhile, worldwide vaccination guidelines recommend measurement of pre-vaccination antibodies instead of regular triennial re-vaccinations in adult dogs. Studies have demonstrated a long lasting duration of immunity against canine parvovirus. Re-vaccination therefore possesses no beneficial effect when dogs already have pre-vaccination antibodies. Thus, when antibodies are present, unnecessary re-vaccinations that potentially cause vaccine-associated adverse events should be avoided. Hemagglutination inhibition and virus neutralization can be performed in specialized laboratories for quantitative antibody titer measurement. Semiquantitative point-of-care (POC) tests for detection of CPV antibodies are available. Since the presence of CPV antibodies in adult dogs that have been vaccinated or previously infected suggests adequate immunity against disease, these POC tests can be a useful tool in practice. They identify dogs that might potentially be unprotected and require re-vaccination during preventive health care appointments. Concerning the POC tests' quality assessment, a high specificity (low number of false positive test results) is considered the most important feature.